Deutsche Bank AG Makes New $3.67 Million Investment in Nurix Therapeutics, Inc. $NRIX

Deutsche Bank AG purchased a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 2nd quarter, HoldingsChannel reports. The fund purchased 151,453 shares of the company’s stock, valued at approximately $3,674,000.

Several other institutional investors have also recently made changes to their positions in NRIX. Larson Financial Group LLC boosted its position in shares of Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after purchasing an additional 1,190 shares in the last quarter. California State Teachers Retirement System raised its stake in Nurix Therapeutics by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock worth $1,290,000 after buying an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management bought a new position in Nurix Therapeutics in the fourth quarter worth approximately $31,000. Royal Bank of Canada grew its stake in Nurix Therapeutics by 17.6% in the fourth quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock valued at $206,000 after acquiring an additional 1,623 shares during the period. Finally, Arizona State Retirement System increased its holdings in shares of Nurix Therapeutics by 8.2% during the fourth quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock valued at $417,000 after acquiring an additional 1,674 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NRIX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Stifel Nicolaus raised their price objective on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, July 10th. UBS Group lifted their price objective on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Nurix Therapeutics in a report on Friday, July 10th. Finally, Wells Fargo & Company cut shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their price target for the company from $28.00 to $25.00 in a research report on Monday, June 8th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.21.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 4,761 shares of Nurix Therapeutics stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer directly owned 40,166 shares in the company, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total value of $108,900.00. Following the sale, the insider directly owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. This represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,314 shares of company stock valued at $589,361 over the last ninety days. 6.70% of the stock is currently owned by company insiders.

Nurix Therapeutics Price Performance

Shares of NRIX stock opened at $26.95 on Wednesday. The firm has a 50-day moving average of $23.82 and a 200-day moving average of $18.79. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $28.23. The company has a market cap of $2.80 billion, a P/E ratio of -7.81 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The firm had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. As a group, research analysts expect that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.